BioMark Wins Peer-Reviewed Validation for AI-Driven Lung Cancer Detection Model

BioMark Diagnostics ( (TSE:BUX) ) has provided an update.

BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harrisburg University of Science and Technology, the study demonstrates that leveraging pathway-based plasma metabolomic biomarkers and interpretability tools such as SHAP analysis can enhance diagnostic accuracy and deepen understanding of the metabolic mechanisms underlying early-stage lung cancer. The publication provides third-party confirmation of BioMark’s long-term investment in AI infrastructure and metabolomic pathway analysis, strengthening its credibility at a time when investors and the healthcare industry are demanding robust proof of concept for AI-enabled medical technologies and reinforcing its positioning at the intersection of oncology, metabolomics and advanced data science.

The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.45 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.

Spark’s Take on TSE:BUX Stock

According to Spark, TipRanks’ AI Analyst, TSE:BUX is a Neutral.

The score is held down primarily by weak financial performance—declining TTM revenue, persistent deep losses, and significant cash burn that implies ongoing external funding risk. Technicals provide a partial offset with a generally improving longer-term trend and neutral momentum. Valuation remains pressured because losses make the P/E non-supportive and no dividend yield data is available.

To see Spark’s full report on TSE:BUX stock, click here.

More about BioMark Diagnostics

BioMark Diagnostics Inc. is a Vancouver-based developer of liquid biopsy tests focused on the early detection of cancer, using metabolomics and machine learning algorithms to analyze biomarkers from a simple blood draw. Its proprietary technology targets earlier diagnosis, assessment of treatment response and potential serial monitoring of cancer survivors, addressing unmet medical needs in oncology through accessible diagnostic solutions.

Average Trading Volume: 16,929

Technical Sentiment Signal: Buy

Current Market Cap: C$49.39M

See more insights into BUX stock on TipRanks’ Stock Analysis page.